Safetychecker Summary
for Risedronate
(for details about the summarized interactions, read the full article)
|
Calcium* |
|
|
Antacids Calcium Food Iron Magnesium Zinc (absorption) Zinc (action) |
|
| Side effect reduction/prevention |
None known |
| Supportive interaction |
None known |
| Adverse interaction |
None known |
Interactions with Dietary Supplements
Calcium and Vitamin D
Short-term treatment with risedronate in people with hyperparathydoidism—a disorder
characterized by high blood levels of calcium—resulted in lower calcium blood
levels.1 Additional research is needed to determine whether people taking
risedronate for Paget’s disease might develop low blood calcium levels. As a precaution,
people with Paget’s disease should take supplemental calcium and vitamin D if dietary
intake is inadequate. However, taking risedronate at the same time as calcium supplements
reduces absorption of the drug.2 Therefore, people taking risedronate for
Paget’s disease should take calcium supplements an hour before or two hours after taking
the drug.
Minerals
Taking risedronate at the same time as iron,
zinc, or magnesium may reduce the amount of drug
absorbed.3 Therefore, people taking risedronate who wish to supplement with these
minerals should take them an hour before or two hours after the drug.
Interactions with Foods and Other Compounds
Antacids
Taking risedronate at the same time as antacids containing calcium or magnesium may reduce absorption of the drug.
Therefore, people taking risedronate should take calcium- or magnesium-containing antacids an
hour before or two hours after the drug.
Food
One controlled study showed that taking risedronate either a half an hour before or two hours
after a meal dramatically reduced absorption of the drug, compared with taking the drug one
hour before or four hours after a meal.4 Consequently, people should take
risedronate one hour before a meal or 4 hours after a meal, as long as the latter is at least
one hour before the next meal.
1. Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067–71.
2. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 2504–6.
3. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc. 2000, 2504–6.
4. Mitchell DY, Heise MA, Pallone KA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999;48:536–42.
Copyright © 2002 Healthnotes, Inc. All rights reserved. www.healthnotes.com
Please read the disclaimer about the limitations of the information provided here. Do NOT rely solely on the information in this article.
Learn more about Healthnotes, the company.
Learn more about the authors of Safetychecker.
The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2003.